TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

MYOVIEW

TECHNETIUM TC-99M TETROFOSMIN KIT
Cardiovascular Approved 1996-02-09
3
Indications
--
Phase 3 Trials
30
Years on Market

Details

Status
Prescription
First Approved
1996-02-09
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

MYOVIEW Approval History

Loading approval history...

What MYOVIEW Treats

4 indications

MYOVIEW is approved for 4 conditions since its original approval in 1996. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Myocardial Ischemia
  • Myocardial Infarction
  • Coronary Artery Disease
  • Heart Disease
Source: FDA Label

Drugs Similar to MYOVIEW

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CARDIOLITE
TECHNETIUM TC-99M SESTAMIBI KIT
3 shared
LANTHEUS MEDCL
Shared indications:
Coronary Artery DiseaseMyocardial IschemiaMyocardial Infarction
FLYRCADO
FLURPIRIDAZ F-18
3 shared
GE HLTHCARE
Shared indications:
Coronary Artery DiseaseMyocardial IschemiaMyocardial Infarction
TECHNETIUM TC 99M SESTAMIBI
TECHNETIUM TC-99M SESTAMIBI KIT
3 shared
JUBILANT DRAXIMAGE
Shared indications:
Coronary Artery DiseaseMyocardial IschemiaMyocardial Infarction
BRILINTA
TICAGRELOR
2 shared
AstraZeneca
Shared indications:
Myocardial InfarctionCoronary Artery Disease
CADUET
AMLODIPINE BESYLATE
2 shared
PHARMACIA
Shared indications:
Coronary Artery DiseaseMyocardial Infarction
PERINDOPRIL ERBUMINE
PERINDOPRIL ERBUMINE
2 shared
Aurobindo Pharma
Shared indications:
Coronary Artery DiseaseMyocardial Infarction
RIVAROXABAN
RIVAROXABAN
2 shared
ALEMBIC
Shared indications:
Coronary Artery DiseaseMyocardial Infarction
TICAGRELOR
TICAGRELOR
2 shared
AMNEAL
Shared indications:
Myocardial InfarctionCoronary Artery Disease
AGGRASTAT
TIROFIBAN HYDROCHLORIDE
1 shared
MEDICURE
Shared indications:
Myocardial Infarction
ALISKIREN HEMIFUMARATE
ALISKIREN HEMIFUMARATE
1 shared
PH HEALTH
Shared indications:
Myocardial Infarction
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM
AMLODIPINE BESYLATE
1 shared
Viatris
Shared indications:
Coronary Artery Disease
AMLODIPINE BESYLATE AND VALSARTAN
AMLODIPINE BESYLATE
1 shared
ALEMBIC
Shared indications:
Coronary Artery Disease
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE
AMLODIPINE BESYLATE
1 shared
STRIDES PHARMA INTL
Shared indications:
Coronary Artery Disease
AMMONIA N 13
AMMONIA N-13
1 shared
BIOMEDCL RES FDN
Shared indications:
Coronary Artery Disease
ATENOLOL
ATENOLOL
1 shared
AIPING PHARM INC
Shared indications:
Myocardial Infarction
ATENOLOL AND CHLORTHALIDONE
ATENOLOL
1 shared
WATSON LABS
Shared indications:
Myocardial Infarction
ATORVALIQ
ATORVASTATIN CALCIUM
1 shared
CMP DEV LLC
Shared indications:
Myocardial Infarction
AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE
AZILSARTAN KAMEDOXOMIL
1 shared
ALKEM LABS LTD
Shared indications:
Myocardial Infarction
AZOR
AMLODIPINE BESYLATE
1 shared
COSETTE
Shared indications:
Myocardial Infarction
BYSTOLIC
NEBIVOLOL HYDROCHLORIDE
1 shared
AbbVie
Shared indications:
Myocardial Infarction
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

MYOVIEW FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

MYOVIEW is a kit for the preparation of technetium Tc99m tetrofosmin for injection. Technetium Tc99m tetrofosmin injection is a radioactive diagnostic agent indicated for the following: Myocardial perfusion imaging under rest and/or exercise or pharmacologic stress conditions to delineate regions of reversible myocardial ischemia or infarcted myocardium in patients with known or suspected coronary artery disease Assessment of left ventricular function (left ventricular ejection fraction and wall motion) in patients with known or suspected heart disease 1.1 Myocardial Perfusion Imaging Myocardi...

MYOVIEW Patents & Exclusivity

Latest Patent: Mar 2030

Patents (1 active)

US9549999 Expires Mar 10, 2030
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.